These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 24211169)

  • 1. A modified surface killing assay (MSKA) as a functional in vitro assay for identifying protective antibodies against pneumococcal surface protein A (PspA).
    Genschmer KR; Accavitti-Loper MA; Briles DE
    Vaccine; 2013 Dec; 32(1):39-47. PubMed ID: 24211169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Modified Surface Killing Assay Distinguishes between Protective and Nonprotective Antibodies to PspA.
    Genschmer KR; Vadesilho CFM; McDaniel LS; Park SS; Hale Y; Miyaji EN; Briles DE
    mSphere; 2019 Dec; 4(6):. PubMed ID: 31826968
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment of a modified opsonophagocytic killing assay for anti-pneumococcal surface protein A antibody.
    Kuroda E; Koizumi Y; Piao Z; Nakayama H; Tomono K; Oishi K; Hamaguchi S; Akeda Y
    J Microbiol Methods; 2023 Sep; 212():106804. PubMed ID: 37543109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modified opsonization, phagocytosis, and killing assays to measure potentially protective antibodies against pneumococcal surface protein A.
    Daniels CC; Kim KH; Burton RL; Mirza S; Walker M; King J; Hale Y; Coan P; Rhee DK; Nahm MH; Briles DE
    Clin Vaccine Immunol; 2013 Oct; 20(10):1549-58. PubMed ID: 23925886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between surface accessibility for PpmA, PsaA, and PspA and antibody-mediated immunity to systemic infection by Streptococcus pneumoniae.
    Gor DO; Ding X; Briles DE; Jacobs MR; Greenspan NS
    Infect Immun; 2005 Mar; 73(3):1304-12. PubMed ID: 15731027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pneumococcal surface protein A is expressed in vivo, and antibodies to PspA are effective for therapy in a murine model of pneumococcal sepsis.
    Swiatlo E; King J; Nabors GS; Mathews B; Briles DE
    Infect Immun; 2003 Dec; 71(12):7149-53. PubMed ID: 14638806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation between in vitro complement deposition and passive mouse protection of anti-pneumococcal surface protein A monoclonal antibodies.
    Khan N; Qadri RA; Sehgal D
    Clin Vaccine Immunol; 2015 Jan; 22(1):99-107. PubMed ID: 25410204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice.
    Nguyen CT; Kim SY; Kim MS; Lee SE; Rhee JH
    Vaccine; 2011 Aug; 29(34):5731-9. PubMed ID: 21696869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetic immunization with the region encoding the alpha-helical domain of PspA elicits protective immunity against Streptococcus pneumoniae.
    Bosarge JR; Watt JM; McDaniel DO; Swiatlo E; McDaniel LS
    Infect Immun; 2001 Sep; 69(9):5456-63. PubMed ID: 11500417
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The proline-rich region of pneumococcal surface proteins A and C contains surface-accessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsis.
    Daniels CC; Coan P; King J; Hale J; Benton KA; Briles DE; Hollingshead SK
    Infect Immun; 2010 May; 78(5):2163-72. PubMed ID: 20194601
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conjugation of PspA4Pro with Capsular Streptococcus pneumoniae Polysaccharide Serotype 14 Does Not Reduce the Induction of Cross-Reactive Antibodies.
    da Silva MA; Converso TR; Gonçalves VM; Leite LCC; Tanizaki MM; Barazzone GC
    Clin Vaccine Immunol; 2017 Aug; 24(8):. PubMed ID: 28637805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective efficacy of PspA (pneumococcal surface protein A)-based DNA vaccines: contribution of both humoral and cellular immune responses.
    Miyaji EN; Dias WO; Tanizaki MM; Leite LC
    FEMS Immunol Med Microbiol; 2003 Jun; 37(1):53-7. PubMed ID: 12770760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mucosal immunization with an unadjuvanted vaccine that targets Streptococcus pneumoniae PspA to human Fcγ receptor type I protects against pneumococcal infection through complement- and lactoferrin-mediated bactericidal activity.
    Bitsaktsis C; Iglesias BV; Li Y; Colino J; Snapper CM; Hollingshead SK; Pham G; Gosselin DR; Gosselin EJ
    Infect Immun; 2012 Mar; 80(3):1166-80. PubMed ID: 22158740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection elicited by nasal immunization with pneumococcal surface protein A (PspA) adjuvanted with bacterium-like particles against Streptococcus pneumoniae infection in mice.
    Li B; Chen X; Yu J; Zhang Y; Mo Z; Gu T; Kong W; Wu Y
    Microb Pathog; 2018 Oct; 123():115-119. PubMed ID: 29959043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of 5-valent conjugate pneumococcal protein A - Capsular polysaccharide pneumococcal vaccine against invasive pneumococcal disease.
    Meng C; Lin H; Huang J; Wang H; Cai Q; Fang L; Guo Y
    Microb Pathog; 2009 Sep; 47(3):151-6. PubMed ID: 19467319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protective Immune Responses Elicited by Fusion Protein Containing PsaA and PspA Fragments.
    Lu J; Sun T; Wang D; Dong Y; Xu M; Hou H; Kong FT; Liang C; Gu T; Chen P; Sun S; Lv X; Jiang C; Kong W; Wu Y
    Immunol Invest; 2015; 44(5):482-96. PubMed ID: 26107747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced protective immunity against pneumococcal infection with PspA DNA and protein.
    Moore QC; Bosarge JR; Quin LR; McDaniel LS
    Vaccine; 2006 Jul; 24(29-30):5755-61. PubMed ID: 16759765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PspA family fusion proteins delivered by attenuated Salmonella enterica serovar Typhimurium extend and enhance protection against Streptococcus pneumoniae.
    Xin W; Li Y; Mo H; Roland KL; Curtiss R
    Infect Immun; 2009 Oct; 77(10):4518-28. PubMed ID: 19687204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Selection of family 1 PspA molecules capable of inducing broad-ranging cross-reactivity by complement deposition and opsonophagocytosis by murine peritoneal cells.
    Goulart C; Darrieux M; Rodriguez D; Pimenta FC; Brandileone MC; de Andrade AL; Leite LC
    Vaccine; 2011 Feb; 29(8):1634-42. PubMed ID: 21211592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rational selection of broadly cross-reactive family 2 PspA molecules for inclusion in chimeric pneumococcal vaccines.
    Converso TR; Goulart C; Rodriguez D; Darrieux M; Leite LCC
    Microb Pathog; 2017 Aug; 109():233-238. PubMed ID: 28602840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.